# A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

> **NCT05164172** · PHASE3 · RECRUITING · sponsor: **H. Lundbeck A/S** · enrollment: 600 (estimated)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Eptinezumab

## Key facts

- **NCT ID:** NCT05164172
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05164172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05164172, "A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05164172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*